VIDEX EC (didanosine) is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) drug used for the treatment of HIV in combination with other antiretroviral medications.
Dosing & Administration
VIDEX EC is used for the treatment of HIV in adults, children, and infants, although it should be used with caution in infants under three months at its recommended dosage. VIDEX EC is available as an extended-release “gastro-resistant” capsule (which cannot be opened, crushed or chewed), or as an oral liquid. It is recommended that the medication be taken on an empty stomach. Additional dosage details are available in the product insert.
As outlined in the product monograph, adjustments in dosage are required for patients with any degree of renal dysfunction. For patients with an underlying liver disease, safety and efficacy for patients has not been established. Extreme caution should be taken for patients who have risk factors for liver disease, or for those with liver dysfunction.
VIDEX EC is contraindicated in patients who are taking stavudine or in those with hypersensitivity to the drug. More details are available in the package insert.
VIDEX EC has been linked with peripheral neuropathy, non-cirrhotic portal hypertension, pancreatitis, osteonecrosis, hepatotoxicity, immune reactivation syndrome, optic nerve lesions, and lipoatrophy. For more details please refer to the package insert.
VIDEX EC has a possible warning for those with lactic acidosis or hepatotoxicity. Risk factors include prolonged therapy, obesity, and being female. Patients with a history of pancreatitis, or who are currently taking medications that have a possible association with pancreatitis, should exercise extreme caution. VIDEX EC has been associated with hepatomegaly with steatosis with a high mortality rate and lactic acidosis. Reading the package insert is highly recommended.
As there is an increased risk of myocardial infarction with the use of VIDEX EC, the underlying risks of patients should be considered before it is prescribed.
Patients who test positive for HIV infection should be screened for comorbid Hepatitis C virus (HCV) infection and Hepatitis B virus (HBV). Patients who are co-infected should begin an antiretroviral regimen that targets co-infected viruses, regardless of viral loads or CD4 counts. Prescribing conditions and drug regimens are outlined within current HIV treatment guidelines.
VIDEX EC is associated with contraindications with a large number of herbal and drug to drug interactions. Details are included in the package insert.
Pregnancy & Lactation
It is recommended that current guidelines be followed when using VIDEX EC in women who are pregnant. Since it is currently unknown whether VIDEX EC is transmitted through breast milk, it is recommended that women who are HIV positive refrain from breastfeeding.
Supportive treatment and close monitoring should be used in the case of an overdose as there is no known antidote.
Reviews are only written by verified customers who have purchased this product.